半乳糖高分子纳米前药构建及肝癌治疗  

Construction of Galactose Polymeric Based Nano-Prodrugs and Liver Cancer Therapy

作　　者：吴婧 李颖 袁嘉怿 陈敬华 WU Jing;LI Ying;YUAN Jia-yi;CHEN Jing-hua(Key Laboratory of Carbohydrate Chemistry and Biotechnology,School of Pharmaceutical Sciences,Jiangnan University,Wuxi 214122,China)

机构地区：[1]江南大学药学院糖化学与生物技术重点实验室,江苏无锡214122

出　　处：《内蒙古大学学报（自然科学版）》2018年第5期515-520,共6页Journal of Inner Mongolia University：Natural Science Edition

基　　金：国家自然科学基金(21574059);中央高校基本科研业务费专项资金(JUSRP51709A)资助项目

摘　　要：用于肝癌治疗的化疗药物存在水溶性差、全身性毒副作用大、没有病灶靶向性等缺陷.研究制备了三种基于半乳糖骨架的还原响应型纳米前药PGal25D、PGal35D和PGal50D,考察其自组装行为,并以PGal25D为药物载体考察其体外药物释放能力及细胞学水平的肝癌治疗效果.结果表明,三种纳米前药均可形成自组装体,其中PGal25D有良好的粒径、载药能力和稳定性;体外药物释放实验证实PGal25D有良好的还原敏感性;体外细胞毒性结果显示,其对肝癌细胞表现出较好的选择性治疗.The chemotherapeutic drugs used for liver cancer therapy had several disadvantages,such as poor water solubility,high systemic toxic and lacking of site-specifically delivering.In current study,three kinds of galactose polymeric based reduced-response nano-prodrugs PGal25 D,PGal35 D,and PGal50 D were prepared and investigated for their self-assembly behaviors.PGal25 D was used as a drug carrier to study drug release capability and cytological treatment of liver cancer.The results showed that all the three nano-prodrugs can form self-assembly,in which PGal25 Dhas good particle size,drug-loading ability and stability.In vitro drug release experiments confirmed that PGa25 Dhas good reduction responsibility,while in vitro cytotoxicity results showed that it showed agood therapeutic selectivity for hepatoma cells.

关 键 词：含糖高分子 纳米前药 还原响应 肝癌 

分 类 号：R944.9[医药卫生—药剂学]